HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) All Versions of this Article: ard.2007.082115v1 67/5/625    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Google Scholar Articles by Martínez-Taboada, V M Articles by Bonilla, G PubMed PubMed Citation Articles by Martínez-Taboada, V M Articles by Bonilla, G Topic Collections Editor's choice

A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects

¹ Division of Rheumatology Hospital Universitario Marqués de Valdecilla. Facultad de Medicina, Universidad de Cantabria, Santander, Spain
² Hospital Universitario Gregorio Marañón, Madrid, Spain
³ Hospital de Donosti, San Sebastían, Guipuzcoa, Spain
⁴ Hospital Universitario La Paz, Madrid, Spain

Correspondence to:
V Rodriguez-Valverde, Facultad de Medicina, Universidad de Cantabria, Rheumatology Division, Hospital Universitario "Marqués de Valdecilla", Avda. Valdecilla s/n 39008, Santander, Spain; rodriguv{at}unican.es

Objective: Open label studies have suggested that tumour necrosis factor (TNF) antagonists led to sustained improvement and corticosteroid sparing effect in patients with giant cell arteritis (GCA). To confirm these observations, we conducted a randomised, double-blind, placebo controlled trial with etanercept in patients with biopsy-proven GCA with side effects secondary to corticosteroids.

Methods: We randomly assigned patients with GCA to receive etanercept (n = 8) or placebo (n = 9) over 1 year together with corticosteroids that were reduced according to a predefined schedule. The primary outcome was the ability to withdraw the corticosteroid therapy and control the disease activity at 12 months.

Results: Baseline characteristics were similar in the two groups, although patients in the etanercept group showed higher levels of basal glycaemia (p = 0.02) and a higher erythrocyte sedimentation rate (ESR) (p = 0.01). After 12 months, 50% of the patients in the etanercept group and 22.2% in the placebo group were able to control the disease without corticosteroid therapy (p value not significant). Patients in the etanercept group had a significant lower dose of accumulated prednisone during the first year of treatment (p = 0.03). There were no differences in the number and type of adverse events.

Conclusion: The limited number of patients included in this study does not allow us to draw definitive conclusions. Etanercept therapy was well tolerated in this aged population. The therapeutic role of etanercept in patients with GCA should be evaluated in studies with a larger number of patients.

This article has been cited by other articles:

				C. Salvarani, N. Pipitone, L. Boiardi, and G. G Hunder Do we need treatment with tumour necrosis factor blockers for giant cell arteritis? Ann Rheum Dis, May 1, 2008; 67(5): 577 - 579. [Full Text] [PDF]